AURA
AURA BIOSCIENCES, INC.
About AURA
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing virus-like drug conjugates (VDCs), a novel class of therapies for the treatment of multiple oncology indications. The Company’s lead VDC candidate, AU-011 (belzupacap sarotalocan), consists of a virus-like particle conjugated with an anti-cancer agent. AU-011 consists of human papilloma virus (HPV)-derived VLP conjugated to hundreds of infrared laser-activated molecules. AU-011 selectively targets and destroys cancer cells and activates the immune system with the potential to create long-lasting anti-tumor immunity. AU-011 is in development for ocular cancers, with an ongoing Phase II dose escalation clinical trial evaluating first-line treatment of choroidal melanoma. It seeks to develop AU-011 across its ocular oncology franchise including for the treatment of patients with choroidal metastases. In addition, the Company is developing AU-011 for the treatment of non-muscle invasive bladder cancer.
Buy US stocks in Australia starting with AURA. Open an account and start investing today!
$414.64M
-
0.00%
83.13K
$12.31
$11.00
$11.11
$24.83
$9.43
AURA FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in AURA
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.